614 related articles for article (PubMed ID: 29231051)
1. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
2. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
7. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
8. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Tollkuci E
J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
[TBL] [Abstract][Full Text] [Related]
10. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Stone RM; Fischer T; Paquette R; Schiller G; Schiffer CA; Ehninger G; Cortes J; Kantarjian HM; DeAngelo DJ; Huntsman-Labed A; Dutreix C; del Corral A; Giles F
Leukemia; 2012 Sep; 26(9):2061-8. PubMed ID: 22627678
[TBL] [Abstract][Full Text] [Related]
11. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
12. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
14. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
16. The importance of FLT3 mutational analysis in acute myeloid leukemia.
Patnaik MM
Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Stone RM; Manley PW; Larson RA; Capdeville R
Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin + Chemo Ups AML Survival.
Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Tvedt TH; Nepstad I; Bruserud Ø
Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
